AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth CareGeographicals
AIDS SerodiagnosisSerologic TestsAntiretroviral Therapy, Highly ActiveHIV InfectionsAnti-HIV AgentsAnti-Retroviral AgentsCD4 Lymphocyte CountHIV-1Viral LoadEnzyme-Linked Immunosorbent AssayHIV SeropositivityAcquired Immunodeficiency SyndromeAntibodies, BacterialSensitivity and SpecificityAntibodies, ViralDrug Resistance, ViralHIVImmunoglobulin MReverse Transcriptase InhibitorsImmunoglobulin GAntigens, BacterialAntibodies, HelminthSyphilis SerodiagnosisAntibodies, ProtozoanRNA, ViralHIV Protease InhibitorsAntigens, ProtozoanAntigens, HelminthInfectious Disease Transmission, VerticalCohort StudiesLamivudineAIDS-Related Opportunistic InfectionsSouth AfricaHepatitis B e AntigensZidovudineOrganophosphonatesViremiaNevirapineMedication AdherenceDrug Therapy, CombinationBenzoxazinesEvaluation Studies as TopicStavudineAgglutination TestsTime FactorsPregnancy Complications, InfectiousToxoplasmosisComplement Fixation TestsHepatitis B, ChronicLyme DiseaseAdenineRitonavirSeroepidemiologic StudiesHIV AntibodiesHemagglutination Inhibition TestsBorrelia burgdorferi GroupUgandaTreatment OutcomeRecombinant ProteinsCross ReactionsLeishmaniasis, VisceralReagent Kits, DiagnosticPatient ComplianceLeishmania infantumProspective StudiesHIV-Associated Lipodystrophy SyndromeLopinavirHemagglutination TestsHepatitis B AntibodiesCD4-Positive T-LymphocytesDog DiseasesImmunoblottingDourineSubstance Abuse, IntravenousDrug Resistance, Multiple, ViralAntiviral AgentsRisk FactorsAIDS Dementia ComplexDNA, ViralGlandersHepatitis CTreatment FailureIndinavirHepatitis BHomosexualityAntibodies, FungalImmune Reconstitution Inflammatory SyndromeHepatitis B virusLeptospirosisIncidenceBotswanaGnathostomiasisImmunoenzyme TechniquesFascioliasisHomosexuality, MaleDisease ProgressionLost to Follow-UpClonorchis sinensisMolecular Sequence DataTuberculosis
DrugsDiseaseTherapyInfectionEmergence of resistanceProphylaxisAcquired immunodeInfectionEvaluateMonthsTreatment
Drugs1
  • OBJECTIVES: To advance the initiative of ending the global epidemic, long-lasting HIV protection is needed through sustained release of antiretroviral drugs for months to years. (cdc.gov)
Disease1
  • HHV-8 is etiologically associated with all forms of Kaposi sarcoma (KS) including classic, endemic, transplant-related, and AIDS-related, as well as rare neoplastic disorders (primary effusion lymphoma [PEL] and solid organ variants) and the lymphoproliferative disorder known as multicentric Castleman's disease (MCD). (hiv.gov)
Therapy1
  • The overall prevalence of KS in the U.S. was as high as 30% among patients with AIDS prior to the advent of effective antiretroviral therapy (ART). (hiv.gov)
Infection1
  • 15-18 A more marked reduction in KS incidence occurred beginning in 1996, shortly after the introduction of protease inhibitor-containing ART in the U.S. Despite these declines, KS is among the most common cancers among the AIDS population in the U.S., 19 and HIV infection increases the risk of KS several thousand fold even in the ART era. (hiv.gov)
Emergence of resistance2
  • Although there is a difference in transmission rates, disease progression, response to antiretroviral therapy, and emergence of resistance to therapy among HIV groups and clades,[13, 14, 15] the most recent enzyme immunoassays are able to detect non-B subtypes. (medscape.com)
  • Diagnosis, antiretroviral ther-apy, and emergence of resistance to antiretroviral agents in HIV-2 infection: a review. (medicinaylaboratorio.com)
Prophylaxis1
  • The administration of antiretrovirals (ARVs) for HIV pre-exposure prophylaxis (PrEP) is highly efficacious and may benefit from new long-acting (LA) drug delivery approaches. (cdc.gov)
Acquired immunode1
  • CDC recommends that all states and territories conduct case surveillance for human immunodeficiency virus (HIV) infection as an extension of current acquired immunodeficiency syndrome (AIDS) surveillance activities. (cdc.gov)
Infection2
  • The expan- sion of national surveillance to include both HIV infection and AIDS cases is a necessary response to the impact of advances in antiretroviral therapy, the implementation of new HIV treatment guidelines, and the increased need for epidemiologic data regarding persons at all stages of HIV disease. (cdc.gov)
  • This report includes a revised case definition for HIV infection in adults and children, recommended program practices, and performance and security standards for conducting HIV/AIDS surveillance by local, state, and territorial health departments. (cdc.gov)
Evaluate2
  • To evaluate the accuracy in identifying recent infections (i.e., within 6 months of seroconversion), we used 216 serum samples from 47 persons whose dates of seroconversion were known. (nih.gov)
  • CDC will provide technical assistance to all state and territorial health departments to continue or establish HIV and AIDS case surveillance systems and to evaluate the performance of their surveillance programs. (cdc.gov)
Months1
  • OBJECTIVES: To advance the initiative of ending the global epidemic, long-lasting HIV protection is needed through sustained release of antiretroviral drugs for months to years. (cdc.gov)
Treatment1
  • To determine the effects of antiretroviral treatment, advanced stage of the disease (i.e., low CD4-cell count), and low HIV viral load on the AI, we analyzed 15 serum samples from 15 persons whose dates of seroconversion were unknown. (nih.gov)